A combination of the new antibiotic TXA709 and existing antibiotic cefdinir has proven successful in treating animals infected with the so-called "superbug" MRSA -- methicillin-resistant staphylococcus aureus.
Although TXA709 is effective on its own in treating MRSA, combining it with cefdinir, which is used to treat a wide range of bacterial infections like strep throat, pneumonia, bronchitis and middle ear and sinus infections, makes it even more efficacious, while also significantly reducing the potential for the MRSA bacteria to become resistant in the future.
What is also good about this experimental treatment is that both drugs can be taken orally, which means they can be administered on an outpatient basis. Only two of the current antibiotics being used clinically to treat MRSA can be administered orally others have to given intravenously.
MRSA can cause a number of problems including skin infections, sepsis and pneumonia. MRSA infections result in many thousands of deaths worldwide.
Current standard-of-care drugs for the treatment of MRSA infections are limited and moreover resistance to these drugs is on the rise and their clinical effectiveness is likely to diminish in the future. Phase 1 clinical trials to test the safety and effectiveness of TXA709 in humans are expected to begin by the end of the year.